REBETOL Drug Patent Profile

« Back to Dashboard

Which patents cover Rebetol, and when can generic versions of Rebetol launch?

Rebetol is a drug marketed by Merck Sharp Dohme and Schering and is included in two NDAs.

The generic ingredient in REBETOL is ribavirin. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the ribavirin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Rebetol

A generic version of REBETOL was approved as ribavirin by ZYDUS PHARMS USA on October 28^th, 2005.

Summary for REBETOL

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	95
Drug Prices:	Drug price information for REBETOL
What excipients (inactive ingredients) are in REBETOL?	REBETOL excipients list
DailyMed Link:	REBETOL at DailyMed

See drug prices for REBETOL

Recent Clinical Trials for REBETOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Tanta University	Phase 2/Phase 3
Memorial Sloan Kettering Cancer Center	Early Phase 1
Weill Medical College of Cornell University	Early Phase 1

See all REBETOL clinical trials

US Patents and Regulatory Information for REBETOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	REBETOL	ribavirin	CAPSULE;ORAL	020903-001	Jun 3, 1998		DISCN	No	No
Merck Sharp Dohme	REBETOL	ribavirin	CAPSULE;ORAL	020903-002	Jul 25, 2001		DISCN	Yes	No
Schering	REBETOL	ribavirin	SOLUTION;ORAL	021546-001	Jul 29, 2003		DISCN	Yes	No

Expired US Patents for REBETOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck Sharp Dohme	REBETOL	ribavirin	CAPSULE;ORAL	020903-001	Jun 3, 1998	4,211,771
Merck Sharp Dohme	REBETOL	ribavirin	CAPSULE;ORAL	020903-001	Jun 3, 1998	4,530,901

EU/EMA Drug Approvals for REBETOL

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp and Dohme B.V	Rebetol	ribavirin	EMEA/H/C/000246Rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.Rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) for paediatric patients (children 3 years of age and older and adolescents) not previously treated and without liver decompensation.	Withdrawn	no	no	no	1999-05-06
Teva B.V.	Ribavirin Teva Pharma B.V.	ribavirin	EMEA/H/C/001064Ribavirin Teva Pharma B.V. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis C (CHC) in adults (see sections 4.2, 4.4, and 5.1).Ribavirin Teva Pharma B.V. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis C (CHC) for paediatric patients (children 3 years of age and older and adolescents) notpreviously treated and without liver decompensation (see sections 4.2, 4.4 and 5.1).	Withdrawn	yes	no	no	2009-07-01
Teva B.V.	Ribavirin Teva	ribavirin	EMEA/H/C/001018Ribavirin Teva is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults, children 3 years of age and older and adolescents and must only be used as part of a combination regimen with interferon alfa-2b. Ribavirin monotherapy must not be used.There is no safety or efficacy information on the use of Ribavirin with other forms of interferon (i.e. not alfa-2b).Naïve patients Adult patients Ribavirin Teva is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for hepatitis C viral ribonucleic acid HCV-RNA.Paediatric patients (children 3 years of age and older and adolescents) Ribavirin Teva is indicated, in a combination regimen with interferon alfa­2b, for the treatment of children and adolescents 3 years of age and older, who have all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, and who are positive for HCV-RNA.When deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that may be irreversible in some patients. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case by case basis.Previous treatment failure patientsAdult patients Ribavirin Teva is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alpha monotherapy but who have subsequently relapsed.	Withdrawn	yes	no	no	2009-03-31
Mylan S.A.S	Ribavirin Mylan (previously Ribavirin Three Rivers)	ribavirin	EMEA/H/C/001185Ribavirin Mylan is indicated for the treatment of chronic hepatitis C and must only be used as part of a combination regimen with interferon alfa-2b (adults, children (three years of age and older) and adolescents). Ribavirin monotherapy must not be used.There is no safety or efficacy information on the use of ribavirin with other forms of interferon (i.e. not alfa-2b).Please refer also to the interferon alfa-2b summary of product characteristics (SmPC) for prescribing information particular to that product.Naïve patientsAdult patientsRibavirin Mylan is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for serum hepatitis-C-virus (HCV) RNA.Children and adolescentsRibavirin Mylan is indicated, in a combination regimen with interferon alfa-2b, for the treatment of children and adolescents three years of age and older, who have all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, and who are positive for serum HCV RNA. When deciding to not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case-by-case basis (see section 4.4).Previously treatment-failure patientsAdult patientsRibavirin Mylan is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alpha monotherapy but who have subsequently relapsed.	Withdrawn	yes	no	no	2010-06-10
BioPartners GmbH	Ribavirin BioPartners	ribavirin	EMEA/H/C/001184Ribavirin BioPartners is indicated for the treatment of chronic hepatitis-C-virus (HCV) infection in adults, children three years of age and older and adolescents and must only be used as part of a combination regimen with interferon alfa-2b. Ribavirin monotherapy must not be used. There is no safety or efficacy information on the use of ribavirin with other forms of interferon (i.e. not alfa-2b).Naïve patientsAdult patientsRibavirin BioPartners is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for hepatitis C viral ribonucleic acid (HCV-RNA) (see section 4.4)Children three years of age and older and adolescentsRibavirin BioPartners is intended for use, in a combination regimen with interferon alfa-2b, for the treatment of children three years of age and older and adolescents, who have all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, and who are positive for HCV-RNA.When deciding to not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case by case basis (see section 4.4).Previous-treatment-failure patientsAdult patientsRibavirin BioPartners is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alfa monotherapy but who have subsequently relapsed (see section 5.1).	Withdrawn	yes	no	no	2010-04-06
Schering-Plough Europe	Cotronak	ribavirin	EMEA/H/C/000247Cotronak is indicated for the treatment of chronic hepatitis C and must only be used as part of a combination regimen with peginterferon alfa-2b or interferon alfa-2b. Cotronak monotherapy must not be used.There is no safety or efficacy information on the use of Cotronak with other forms of interferon (i.e., not alfa-2b).Please refer also to the peginterferon alfa-2b or interferon alfa-2b Summary of Product Characteristics (SPC) for prescribing information particular to that product.	Withdrawn	no	no	no	1999-05-07

International Patents for REBETOL

See the table below for patents covering REBETOL around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	199463	SINTESIS DE NUCLEOSIDOS DE 1,2,4-TRIAZOL-3-SUSTITUIDOS
Argentina	205339	SINTESIS DE 1,2,4-TRIAZOLO-3-CARBOXAMIDAS UTILES COMO AGENTES ANTIVIRALES
Argentina	207138	METODO PARA LA OBTENCION DE 1,2,4-TRIAZOLES N-SUBSTITUIDOS Y SUS SALES DE ADICION
Argentina	224992	METODO PARA LA OBTENCION DE NUCLEOSIDOS DE 1-(BETA-D-RIBOFURANOSIL)-1,2,4-TRIAZOL-3-CARBOXAMIDA
Austria	336199
Austria	A465772
Australia	4215772

Last updated: June 13, 2026

Rebetol (ribavirin) market dynamics and financial trajectory

Rebetol (ribavirin) is a legacy antiviral with a shrinking addressable market driven by curative direct-acting antiviral (DAA) regimens for hepatitis C. Revenue has trended down as treated patient volumes migrated from interferon-based therapy plus ribavirin to DAA combinations without ribavirin. Current market dynamics are dominated by (1) remaining interferon/ribavirin use pockets, (2) generic ribavirin competition, and (3) pricing pressure in older, off-patent supply.

What drives Rebetol (ribavirin) demand in 2026

Rebetol is ribavirin for antiviral treatment regimens historically used for hepatitis C virus (HCV) in combination with peginterferon alfa (and in some settings with interferon alfa/ribavirin), with the primary clinical rationale rooted in interferon-era regimens.

How has hepatitis C prescribing shifted away from ribavirin

Rebetol’s core demand engine was peginterferon plus ribavirin for chronic HCV. Over the past decade, HCV treatment shifted to interferon-free DAAs (NS3/4A protease inhibitors, NS5A inhibitors, NS5B polymerase inhibitors). Those DAAs generally reduce or eliminate ribavirin need because they achieve high sustained virologic response (SVR) rates without interferon-era combination dependence.

Net effect on market dynamics

• Lower treated volumes under “peginterferon + ribavirin” protocols.
• Reduced ribavirin “add-on” utilization where ribavirin was previously used to manage difficult-to-treat patient subgroups (depending on era, genotype, prior treatment status, and guideline changes).
• A long-term category headwind as the global HCV treatment population matures and non-curative drivers decline.

What patient segments still create ribavirin demand

Residual demand tends to be concentrated in:

• Historical or constrained-access care pathways that lag DAA adoption.
• Specific clinician/payer decisions where ribavirin is retained as part of older regimens (practice heterogeneity persists by country, budget constraints, and formulary logic).
• Ongoing use in off-label or legacy indications in certain jurisdictions, though the dominant commercial narrative remains HCV interferon-era therapy.

How do generic ribavirin and biosupply affect Rebetol pricing and volume

Rebetol is marketed as branded ribavirin, but ribavirin is widely available as generics in multiple dose forms and strengths.

Market structure

• Branded Rebetol competes against multiple generic ribavirin suppliers, typically exerting strong price pressure.
• Wholesaler buying and payer reimbursement typically favor lower net-cost generics, accelerating substitution once branded value is not tied to supply assurances, contract positioning, or margin-sharing.

Pricing mechanics

In mature off-patent small-molecule markets:

• List price has limited relevance; net price is driven by rebates, contracts, and tender dynamics.
• Competitive interchangeability compresses gross margin and pushes branded manufacturers to defend share via contracting or narrower procurement niches.

Supply and continuity

Ribavirin is a commodity-like molecule with multiple sources. The market can still experience availability shocks at times, but those events usually redistribute volume rather than create durable branded premium economics.

What is the financial trajectory for Rebetol revenue and profitability

Rebetol’s financial trajectory follows a predictable pattern for legacy specialty small molecules displaced by curative standard-of-care:

1. Peak-era revenues were tied to interferon-era HCV treatment adoption.
2. Structural decline followed the rollout of interferon-free DAAs, with reduced ribavirin co-therapy.
3. Branded economics deteriorated as generic ribavirin substitution increased and net pricing fell.
4. Earnings contribution shifted from growth to margin defense and lifecycle management, with branded revenue becoming small relative to the modern antiviral portfolio mix of incumbent firms.

Featured snippet: Why Rebetol revenues decline

Rebetol revenues decline because ribavirin is no longer required in most current hepatitis C regimens, while generic ribavirin captures remaining demand at lower net cost.

When does Rebetol lose exclusivity, and what does that imply for market share

Rebetol’s commercial exclusivity is fully matured in practice. The drug is legacy ribavirin; brand exclusivity is not the dominant driver of current access. The binding reality for market share is generic interchangeability and payer contract strategy rather than regulatory exclusivity timelines.

What this implies for branded share

• Brand share is primarily defended in limited contract sets.
• When formularies update to generic-preferred positions, branded share typically erodes rapidly.
• Branded manufacturers focus on pharmacy benefit design, rebate structures, and supply agreements rather than exclusivity leverage.

What is the competitive landscape for ribavirin in hepatitis C

Direct substitution with generic ribavirin

Competition is largely within ribavirin itself:

• Multiple generic manufacturers.
• Multiple dosage presentations (oral solid forms) aligned to historical ribavirin dosing used in combination protocols.

Indirect competition from DAAs

The bigger competitive displacement is not “ribavirin versus ribavirin,” but “ribavirin versus interferon-free HCV cures.”

• DAAs can treat without ribavirin, so the TAM for ribavirin shrinks even if ribavirin continues to be available.
• That TAM shrink affects both branded and generic.

How does Rebetol compare with competing HCV therapies on market adoption

Rebetol competes with two distinct groups:

1) Ribavirin-only competitors

• Branded ribavirin vs generic ribavirin
• Economics are determined by net pricing and contract placement.

2) Standard-of-care displacement

• Interferon-containing regimens are obsolete in most guideline-consistent markets.
• DAAs are the growth engine, so ribavirin is a declining co-therapy category.

Practical business result: Even where ribavirin remains clinically discussed, current prescribing is dominated by DAA-driven protocols.

What FDA regulatory status matters for Rebetol’s commercialization

Rebetol is an FDA-approved ribavirin product for approved indications historically tied to HCV treatment combinations. Current commercialization is shaped by:

• Ongoing availability of approved labeling and dosing,
• Generics’ presence across the same active ingredient,
• Practical prescribing patterns based on contemporary guidelines.

Orange Book-driven access logic

For mature small molecules like ribavirin, branded access is typically constrained by:

• Expired or expiring patents (at earlier times in the lifecycle),
• Broad generic entry and substitution dynamics.

What patent estate issues would matter for a new competitor seeking market entry

Because ribavirin is long-displaced from a novelty lifecycle, new entrants rarely pursue brand-style patent thickets. The strategic barriers, if any, are more likely to involve:

• Formulation-specific improvements (where protected, if still active, in some jurisdictions),
• Manufacturing process or polymorph-related patents in niche cases,
• New dosing forms or pediatric formulations (if protected), though this is less relevant for ribavirin’s mature market.

Business implication: Market entry economics are dominated by generic cost position and regulatory/CMC readiness rather than exclusivity capture.

What generic entry risks exist for Rebetol

For branded Rebetol, “generic entry risk” is largely historical because ribavirin is already widely generified. Current commercial risk for the brand is:

• Continued generic substitution and contract tightening.
• Any additional price erosion from new low-cost supply or consolidation in generic supply chains.
• Limited upside from switching behavior because ribavirin lacks the differentiation that typically supports durable premium pricing.

How much revenue is exposed to HCV guideline changes

Rebetol’s revenue is exposed to:

• The rate of DAA adoption in remaining ribavirin-using cohorts.
• Updates to payer criteria and prescriber guideline adherence.
• Continued movement toward ribavirin-free regimens in any setting where ribavirin was previously used as a co-therapy.

Because DAAs are curative and ribavirin-free protocols are preferred, guideline shifts mechanically reduce ribavirin utilization and compress future revenue potential.

Geographic dynamics: where Rebetol tends to hold on longest

Rebetol-style brands often persist longer in:

• Markets with slower DAA adoption due to reimbursement constraints or procurement cycles.
• Regions where prescribing practices lag guideline updates.
• Countries where ribavirin remains in formulary due to legacy regimen presence and clinician inertia.

But in global markets, generic ribavirin is still the primary beneficiary of residual demand, so branded economics remain pressured.

Key metrics to track for Rebetol’s financial trajectory

For investors or licensing/commercial teams assessing legacy antiviral performance, track:

• US and EU pharmacy claims for ribavirin prescriptions (brand vs generic mix).
• HCV treatment mix by regimen class (DAA-only vs combination regimens).
• Average selling price and net price trends in ribavirin.
• Formulary inclusion in major payers and contract rebate pressure.
• Wholesale inventory and supply continuity indicators (can transiently alter volumes).

Key Takeaways

• Rebetol’s market dynamics are dominated by structural displacement of interferon-based HCV regimens by interferon-free DAAs that do not require ribavirin.
• Competitive pressure is intense due to broad generic ribavirin availability, driving net price compression and limiting branded share growth.
• Financial trajectory is consistent with a legacy antiviral: long-term decline in addressable use, margin pressure from substitution, and only localized residual demand where older regimens persist.
• Future volume exposure is primarily tied to the remaining pockets of ribavirin-using care pathways and the speed of DAA adoption by payer and guideline dynamics.

FAQs

1) Is Rebetol still used for hepatitis C treatment today?

Rebetol remains available, but current standard-of-care in most guideline-consistent settings uses interferon-free DAA regimens that typically eliminate the need for ribavirin.

2) Does ribavirin still have any role in modern HCV regimens?

Ribavirin can appear in limited scenarios in legacy or specific clinical decisions depending on geography and care pathways, but it is not part of the dominant modern HCV regimen landscape.

3) Will new DAAs reduce ribavirin demand further?

Any further expansion of ribavirin-free DAA use in additional patient cohorts reinforces the downtrend in ribavirin utilization.

4) What matters more for Rebetol profitability: volume or net pricing?

Both are pressured; however, net pricing compression from generic substitution is typically the faster driver of branded margin deterioration once prescribing shifts.

5) How should a company assess residual market opportunities for ribavirin?

Use claims-based shares, payer formulary status, and regimen mix data to quantify residual interferon-era combination use and local payer behavior that still supports ribavirin co-therapy.

References

1. U.S. Food and Drug Administration. Rebetol (ribavirin) prescribing information. FDA label.
2. American Association for the Study of Liver Diseases. Hepatitis C guidance and regimen updates (interferon-free standard-of-care evolution).